Highlights Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
76.67 ^USD	-3.79%		+5.48%	+15.48%

05-08	RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating	MT
05-08	Arrowhead Pharmaceuticals, Inc., Q2 2026 Earnings Call, May 07, 2026

Highlights

05-07	Arrowhead Pharmaceuticals Swings to Fiscal Q2 Loss, Revenue Falls	MT
05-07	Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Loss $0.93, vs. FactSet Est of $1.10 Loss	MT
05-07	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
05-07	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q2 Revenue $73.7M, vs. FactSet Est of $73.8M	MT
05-05	Arrowhead Pharmaceuticals Announces Exclusive Worldwide License Agreement with Madrigal Pharmaceuticals for ARO-PNPLA3	CI
05-01	Arrowhead Pharmaceuticals Inc Receives Tga Approval of Redemplo in Australia Expanding Global Access for Patients with Familial Chylomicronemia Syndrome	CI
04-24	Arrowhead Pharmaceuticals Gets Positive Opinion for Redemplo to Treat Rare Lipid Disorder in Europe	MT
04-24	EU Medicines Agency Committee Recommends Arrowhead's Redemplo for Approval	MT
04-24	Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval Of REDEMPLO To Reduce Triglycerides In Adults With Familial Chylomicronemia Syndrome In Europe	CI
03-28	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran Across A Spectrum Of Hypertriglyceridemia	CI
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-27	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	CI
01-07	Arrowhead Pharmaceuticals' Redemplo Approved in China; Triggers $10 Million Payment From Sanofi	MT
01-07	Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo for Familial Chylomicronemia Syndrome in China	CI
01-06	Arrowhead Pharmaceuticals, Inc. Announces Interim Clinical Data on RNAi-Based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition	CI
01-05	Arrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome	CI
01-05	Arrowhead Pharmaceuticals Says Health Canada Issues 'Notice of Compliance' for Redemplo for Triglyceride Disorder	MT
01-05	Arrowhead Pharmaceuticals announces Health Canada approval of Redemplo(TM)	RE
12-15	Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
12-08	Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies	CI
12-02	Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran	RE
12-02	Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia	CI
11-25	Arrowhead Pharmaceuticals Fiscal-Year Loss Narrows, Revenue Rises	MT